[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier Princesse Grace\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":121},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,72,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100644741","comparison-of-oral-administration-of-a-jak-inhibitor-in-rheumatoid-arthritis-100644741",false,"NCT07674134","Comparison of Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis","Comparison of Morning Versus Evening Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis","JAK-INHI","Inclusion Criteria:\n\n* Patient aged over 18 years\n* Patient with Rheumatoid Arthritis according to the 2010 ACR\u002FEULAR criteria\n* Patient meeting the criteria for initiation of a JAK inhibitor according to the marketing authorization and international recommendations\n* Patient capable of providing informed, written, dated, and signed consent before the start of any trial-related procedure.\n\nExclusion Criteria:\n\n* No contraindication to a bDMARD\n* Not stable dose of corticosteroids in the 4 weeks preceding enrollment\n* Not stable dose of maintenance therapy (methotrexate, leflunomide, hydroxychloroquine, cyclosporine, gold salts) in the 4 weeks preceding enrollment\n* Prior treatment with a JAK inhibitor\n* Patient unable to be followed-up in the study during 6 months\n* Minors or adults under guardianship or curatorship, or deprived of their liberty\n* Pregnant or breastfeeding patient\n* Patient refusing to use an effective method of contraception for the duration of the study\n* Person not affiliated with a social security scheme.","ALL","18 Years",{"count":20,"type":21},90,"ESTIMATED","OBSERVATIONAL","The aim of this study is to offer patients two treatment options: morning or evening administration of a JAK inhibitor prescribed within the framework of its marketing authorization, according to the EULAR response.\n\nThe objective is to determine whether evening administration in our patients with rheumatoid arthritis provides greater efficacy than morning administration in our patients taking JAK inhibitors once daily.",[25],"Rheumatoid Arthritis (RA)",[27],"JAK inhibitor","RECRUITING","2026-06-23",{"date":31,"type":32},"2026-06-29","ACTUAL",{"date":34,"type":32},"2024-04-23",{"date":36,"type":21},"2026-11",{"name":38,"class":39},"Centre Hospitalier Princesse Grace","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":40},"100639599","pain-assessment-during-rapid-sequence-induction-100639599","NCT07588165","Pain Assessment During Rapid Sequence Induction","Nociception Assessment During Rapid Sequence Induction: A Prospective Observational Study of Practices and Complications - The NARSI Study","NARSI","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Patient requiring tracheal intubation after rapid sequence induction in the visceral surgery operating room\n* Pain monitoring by Analgesia Nociception Index (ANI) as part of general anesthesia\n\nExclusion Criteria:\n\n* Patient with atrial fibrillation at the time of intubation following rapid sequence induction\n* Patient on long-term beta-blocker therapy",{"count":50,"type":21},150,"Rapid sequence induction (RSI) is a standard anesthesia technique used in patients at risk of aspiration. Although tracheal intubation following RSI is a frequent and painful procedure, no study has yet evaluated nociception using the Analgesia Nociception Index (ANI) during this procedure.\n\nThis monocentric prospective observational study aims to describe the impact of RSI on pain measured by ANI, and to explore early complications (desaturation, hypotension, regurgitation) and factors associated with pain and complications. 150 patients undergoing RSI in the visceral surgery operating room at CHPG Monaco will be analyzed.",[53,54,55,56],"Rapide Sequence Induction","Tracheal Intubation","Nociception","General Anesthesia",[58,59,60,61,62,63],"Analgesia Nociception Index (ANI)","Rapid Sequence Induction (RSI)","Pain monitoring","Tracheal intubation","Hemodynamic response","General anesthesia","2026-05-22",{"date":66,"type":32},"2026-05-27",{"date":68,"type":32},"2026-05-21",{"date":70,"type":21},"2028-05",{"name":38,"class":39},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100507295","glial-fibrillary-acidic-protein-gfap-and-ubiquitin-carboxy-terminal-hydrolase-l1-uch-l1-to-exclude-lesions-linked-to-significant-traumatic-brain-injuries-100507295","NCT05885529","Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1) to Exclude Lesions Linked to Significant Traumatic Brain Injuries","Added Value, Performance and Acceptance of the \"GFAP-UCH-L1\" Pair in the Evaluation of Subjects with Mild Traumatic Brain Injury (MTBI) At Intermediate Risk of Complications","GUEST","Inclusion Criteria:\n\n* Traumatic brain injury defined by\n\n  * Impact on the skull or the face AND OR\n  * Acceleration \u002F deceleration\n* Glasgow Coma Scal 13, 14 or 15\n* One of the following 4 criteria:\n\n  * \\> 65 years treated with anti-platelet agent,\n  * GCS \\\u003C 15 two hours after the trauma if associated intoxication (alcohol, narcotic, psychotropic),\n  * Trauma with high kinetics (for information only: a risk mechanism (pedestrian knocked down by a motorized vehicle, ejection from a vehicle, fall from more than 3 steps (more than one meter), etc.),\n  * Amnesia of facts \\> 30 min before the trauma.\n* Having a blood sample taken as part of care with a delay between the clinical event and the biological sample \\\u003C 12 hours\n* Having a CT-scan prescription as part of the MTBI evaluation\n* Patient who signed an informed consent form\n\nExclusion Criteria:\n\n* Person not affiliated or not benefiting from a health insurance scheme.\n* Person under judicial protection.\n* Person with restrictions of freedom or subject to Articles L.3212-1 and L.3213-1, and not included in Article L.1122-8 of the French CSP\n* Blood collection time \\> 12 hours\n* Subjects for which a scan would be carried out systematically, including:\n\n  * GCS \\\u003C13 (moderate or severe trauma),\n  * congenital hemostasis disorders or patient on anti-coagulant treatment,\n  * clinical signs evoking a fracture of the vault or the base of the skull,\n  * more than one episode of vomiting,\n  * post-traumatic convulsion,\n  * focal neurological deficit.\n* Obstacle to follow-up at D7\n* Malignant melanomas",{"count":81,"type":21},1500,"The goal of this observational study is to evaluate the performance of UCH-L1 and GFAP combined in patients with a mild traumatic brain injury. The main question :\n\n• Does the combination of UCH-L1 and GFAP can exclude brain injuries detected with CT scan in the first twelve hours after a mild traumatic brain injury?\n\nParticipants will do the exams planed in routine care and :\n\n* during the expected blood sampling an additional blood sample will be done,\n* seven days after the discharge a call will be done by the investigator.",[84],"Traumatic Brain Injury",[86,87,88],"UCHL1","GFAP","CT scan","2025-02-17",{"date":91,"type":32},"2025-02-19",{"date":93,"type":32},"2024-04-19",{"date":95,"type":21},"2026-03-30",{"name":38,"class":39},15,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":106,"studyType":22,"phases":4,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":40},"100491293","observational-study-on-the-treatment-of-trigeminal-neuralgia-by-radiosurgery-100491293","NCT05677243","Observational Study on the Treatment of Trigeminal Neuralgia by Radiosurgery","NATURE","Inclusion Criteria:\n\n* Classical trigeminal neuralgia according the International Classification of Headache Disorders\n* Trigeminal neuralgia resistant to the maximum tolerated medical therapy, with pain intensity according to the Barrow Neurological Institute (BNI) score IV or V.\n* Patients aged \\> 18\n\nExclusion Criteria:\n\n* Patients suffering from secondary Trigeminal neuralgia (tumour in the cerebellopontine angle, arteriovenous malformation or multiple sclerosis)\n* Previous history of radiosurgery procedure",{"count":50,"type":21},"10 Years","This study aims to evaluate the outcome of patient treated by radiosurgery on LINAC with high dose rate for classical trigeminal neuralgia",[109],"Trigeminal Neuralgia",[109,111,112,113,114],"Radiosurgery","LINAC","Pain relief","Hypesthesia",{"date":91,"type":32},{"date":117,"type":32},"2021-12-15",{"date":119,"type":21},"2036-12",{"name":38,"class":39},""]